Ticker LaunchDirect listing · PHAR
Pharming Group N.V.
Pharming Group N.V. (PHAR) went public through a direct listing on Nasdaq Global Market on Dec 23, 2020. Cooley advised the company.
Pharming Group N.V. is a commercial-stage biopharmaceutical company developing protein replacement therapies and precision medicines for rare diseases. Its lead product, RUCONEST, is a plasma-free recombinant C1 esterase inhibitor approved for acute hereditary angioedema attacks, sold in the United States, European Union and United Kingdom.
- Status
- Direct listing
- Ticker
- PHAR
- Exchange
- Nasdaq Global Market
- Listed
- Dec 23, 2020
- First filed
- Nov 25, 2020
- Company counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- Netherlands
More on this listing for subscribers
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Nov 25, 2020
- Latest amendment Dec 22, 2020
- Final prospectus (424B4) Dec 23, 2020
- All filings on EDGAR CIK 1828316
Other Biotech & pharma direct listings in 2020
- Silence Therapeutics plcSLN · Sep 8, 2020